Cholangiocarcinoma: Research Studies

7 Related Result(s)

  1. A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

    This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that...

  2. DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

    This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may...

  3. Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms

    The primary objective is to determine the response rate for subject with mutations in BAP1 and other genes...

  4. A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

    The primary objective is to determine and compare the overall survival of patients with advanced Hepatocellular Carcinoma or liver cancer, without prior...

  5. Target HCC

    TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of...

  6. Phase II Trial of Niraparib in BAP1 and other DDR Deficient Neoplasms (UF-STO-ETI-001)

    The purpose of this study is to investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage...

  7. A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

    A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy ...